Business Context and Reporting Period
Company: InspireMD, Inc. (NSPR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: InspireMD is a medical device company focused on the CGuard™ stent platform for treating carotid artery disease. In June 2025, the company received FDA PMA approval and CE Mark approval for its next-generation CGuard Prime system, officially launching commercial sales in the U.S. in July 2025. Operations and manufacturing are primarily located in Israel, with a new global headquarters established in Miami, Florida.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues | $2,523 | $1,810 | $5,830 | $5,060 |
| Gross Profit | $864 | $414 | $1,469 | $1,037 |
| Gross Margin | 34.2% | 22.9% | 25.2% | 20.5% |
| Net Loss | $(12,708) | $(7,890) | $(37,025) | $(22,831) |
| Operating Cash Flow | — | — | $(25,758) | $(15,118) |
| Cash & Equivalents (End of Period) | $63,403 | — | $63,403 | — |
| Total Assets | $78,472 | — | $78,472 | — |
| Total Liabilities | $14,358 | — | $14,358 | — |
Note: Q3 2024 cash balance was $15,818 (end of period). Q3 2025 cash balance is $63,403.
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 39.4% year-over-year, driven by the U.S. commercial launch of CGuard Prime and continued international distributor sales. U.S. revenue specifically jumped from $7,000 in Q3 2024 to $497,000 in Q3 2025.
- Expense Expansion: Operating expenses surged due to U.S. commercialization efforts. Selling and Marketing expenses increased 198.4% in Q3 2025 (to $4.4M) and General and Administrative expenses rose 68.8% (to $5.9M), primarily due to headcount increases and professional services.
- Liquidity Position: Cash and cash equivalents increased significantly from $18.9M at year-end 2024 to $63.4M at September 30, 2025. This was fueled by a $40.1M private placement in July 2025 and $16.9M from the exercise of Series I warrants.
- Inventory Build: Inventory increased to $3.6M from $2.6M at year-end 2024, reflecting preparation for U.S. commercial sales.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern. Despite the recent capital raise, the company expects to continue incurring losses and negative operating cash flows until CGuard Prime reaches commercial profitability. Current resources may not be sufficient to fund operations for the next 12 months without additional financing.
- Commercial Strategy: The company is transitioning from a development-stage to a commercial-stage entity in the U.S., utilizing a direct sales organization. Success depends on market acceptance, reimbursement rates, and the ability to scale manufacturing (currently transitioning to a contract manufacturer in North Carolina).
- Geopolitical Risk: Operations and manufacturing are located in Israel. While a ceasefire was reached in October 2025, the region remains volatile. The company notes that while current operations are largely unaffected, escalation could materially impact supply chains and personnel.
- Capital Needs: The company plans to raise additional capital through equity sales, debt, or strategic partnerships. Failure to secure funding could force a reduction in activities or cessation of operations.
Investor Verification Checklist
- Runway Analysis: Verify the specific burn rate and projected months of cash remaining given the "substantial doubt" disclosure and high operating expenses.
- U.S. Sales Momentum: Monitor subsequent quarterly reports for the sustainability of U.S. revenue growth following the initial launch spike.
- Manufacturing Transition: Confirm the timeline and success of transferring full-scale production to the Aptyx facility in North Carolina to mitigate Israeli geopolitical risk.
- Reimbursement Status: Track the status of Medicare and private payer reimbursement approvals for CGuard Prime in the U.S., which is critical for volume adoption.
- Dilution Risk: Review the terms of outstanding warrants (Series J and K) and pre-funded warrants, as future exercises or new equity raises may significantly dilute existing shareholders.